
CAR T-Cell therapy is the best treatment for relapsed and recurring multiple myeloma
Discover why CAR T-cell therapy stands out as the premier option for relapsed and recurring multiple myeloma cases. Explore its groundbreaking approach in leveraging the body's immune system to target cancer cells, offering renewed hope and improved outcomes. Uncover the transformative potential of this innovative treatment modality.

IASO Bio launches fully human BCMA CAR T for multiple myeloma
Learn about IASO Bio's groundbreaking launch of a fully human BCMA CAR T-cell therapy for multiple myeloma. Explore the cutting-edge technology behind this innovative treatment, offering new avenues of hope for patients. Delve into the future of cancer care with this remarkable advancement in precision medicine.